CTRI/2011/09/002030已完成2 期
Comparative Efficacy, Safety and Tolerability of Silver Sulfadiazine Cream (Nanonized) and Silverex Cream in the Prophylaxis of Infection in Burn Wounds - An Open-label, Randomized, Pilot Study
Ranbaxy Laboratories Ltd0 个研究点目标入组 36 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Subjects who have given written informed consent to participate in the study.
- •2. Subjects of either sex aged between 18 and 65 years (both inclusive) with partial thickness burns of thermal origin covering 10% of the TBSA and suitable for outpatient management.
- •3. Subjects in whom burn injury is 24 hours old at the time of screening.
- •4. Subjects with clean, non-infected wound as judged by the investigator.Presence of infection will be judged clinically by symptoms and signs that include purulent drainage, erythema, warmth, exudation, malodor, pain and/or fever.
排除标准
- •1.Subjects with history of hypersensitivity to silver sulfadiazine, other sulfonamides, chlorhexidine or any of the excipients of study formulations#.
- •2.Subjects with burn wounds associated with chemical, electrical or inhalational injury.
- •3.Subjects with full thickness burns (a burn involving destruction of the entire epidermis and dermis, leaving no residual epidermal cells to repopulate) or circumferential burns (a burn which encircles an entire body part) or superficial burn (a burn which remains confined to the epidermis).
- •4.Subjects with burns involving genitalia, head (including face), perineum or major joints.
- •5.Subjects with burns of hands or feet likely to cause functional impairment.
- •6.Subjects with burn wounds not expected to heal within 21 days or requiring systemic antimicrobial treatment or surgical intervention (except surgical debridement) during the study.
- •7.Subjects with burn wounds expected to heal in less than 7 days.
- •8.Subjects with burns and concomitant trauma (such as fractures) in which the burn injury poses the greatest risk of morbidity and mortality.
- •9.Burn injury in subjects with preexisting medical disorders (e.g., diabetes mellitus, cancer or other immunocompromising conditions) that could complicate management, prolong recovery, or affect mortality.
- •10.Subjects who are under treatment with topical or systemic steroid medications or immunosuppressive agents.
- •11.Subjects with significant disease(s) or disorder(s) other than burn injury that in the opinion of the investigator may (i) put the subject at risk because of participation in the study (ii) interfere with the study evaluations or (iii) cause concern regarding subject?s ability to participate in the study.
研究者
相似试验
已完成
3 期
anonized Silver Sulfadiazine Cream in prevention of Infections in Burn woundsCTRI/2014/11/005188Sun Pharmaceutical Industries Limited250
尚未招募
不适用
Comparison of two inject able iron preparations for treatment of iron deficiency anemia in pregnancyCTRI/2019/02/017553Department of Obstetrics and Gynecology
尚未招募
Unknown
Effect of products on pimplesCTRI/2024/08/072208KOP research centre private limited
已完成
3 期
Cefozopran injection in treatment of community acquired pneumoniaCTRI/2013/02/003366Ranbaxy Research Laboratories100
已完成
3 期
Cefozopran injection in treatment of complicated urinary tract infection and pyelonephritisCTRI/2013/02/003340Ranbaxy Laboratories Ltd100